Analyst Price Targets — BVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 11:07 am | — | Canaccord Genuity | $19.00 | $14.26 | TheFly | Bioventus price target raised to $19 from $15 at Canaccord |
| August 6, 2026 1:24 pm | — | Craig-Hallum | $18.00 | $13.87 | TheFly | Bioventus price target raised to $18 from $16 at Craig-Hallum |
| August 6, 2026 11:56 am | — | Barrington | $18.00 | $15.26 | TheFly | Bioventus price target raised to $18 from $14 at Barrington |
| June 16, 2026 10:37 am | Caitlin Cronin | Canaccord Genuity | $15.00 | $8.60 | StreetInsider | Canaccord Reiterates Buy Rating on Bioventus Inc (BVS) |
| February 9, 2026 12:55 pm | — | Barrington | $13.00 | $8.51 | TheFly | Bioventus initiated with an Outperform at Barrington |
| May 7, 2025 1:16 pm | Chase Knickerbocker | Craig-Hallum | $15.00 | $6.20 | TheFly | Bioventus price target lowered to $15 from $17 at Craig-Hallum |
| October 1, 2024 1:38 pm | Caitlin Cronin | Canaccord Genuity | $12.00 | $11.79 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS) |
| August 7, 2024 9:05 am | Chase Knickerbocker | Craig-Hallum | $12.00 | $8.25 | TheFly | Bioventus price target raised to $12 from $9 at Craig-Hallum |
| May 7, 2024 1:38 pm | William Plovanic | Canaccord Genuity | $8.00 | $5.12 | StreetInsider | Bioventus Inc (BVS) PT Raised to $8 at Canaccord Genuity |
| March 13, 2024 8:42 am | Alex Nowak | Craig-Hallum | $9.00 | $5.29 | StreetInsider | Bioventus Inc (BVS) PT Raised to $9 at Craig-Hallum |
Latest News for BVS
Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Bioventus NASDAQ: BVS reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BVS.
U.S. House Trading
No House trades found for BVS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.